We are pleased to announce that MindBio’s scientific team has completed a world-first phase 1 clinical trial microdosing LSD to clinical trial participants who take the drug at home and out in the community in the same way they would take any other medication.

Excerpt from the Market Announcement:

Vancouver, British Columbia – May 3 rd , 2022 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that MindBio Therapeutics (“MindBio”) has completed its 12-month Phase 1 clinical trial microdosing LSD in 80 healthy participants. MindBio is developing a microdosing regimen using LSD to treat mental health disorders such as depression. To get these…